SYNB1020
- Generic Name
- SYNB1020
- Drug Type
- Biotech
- Background
SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study.
Safety, Tolerability and Pharmacodynamics of SYNB1020
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 23
- Registration Number
- NCT03447730
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸Texas Liver Institute, San Antonio, Texas, United States
Safety and Tolerability of SYNB1020-CP-001
- Conditions
- Healthy VolunteerUrea Cycle Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 52
- Registration Number
- NCT03179878
- Locations
- 🇺🇸
Parexel, Brooklyn, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.